For the 5th year in a row DFE Pharma is organising the Dry Powder Inhalation China technology conference in Shanghai, China (March 22nd - 24th, 2017). Last year this growing event was attended by over 200 inhalation industry professionals ranging from R&D and General Management to government officials, signalling the growing importance of DPI formulations for the Chinese Pharmaceutical industry.
As of 24th of October DFE Pharma offers a new specialty grade SuperTab® 40LL. SuperTab® 40LL is the newest product in DFE Pharma’s extensive direct compression portfolio composed of (anhydrous) lactose (95% w/w) and lactitol monohydrate (5% w/w).
As of 1 November 2015, Bas van Driel has been appointed Chief Executive Officer (CEO) of DFE Pharma. He will take over Jan Jongsma’s responsibilities. Bas van Driel will continue the pursuit of DFE Pharma to be leading in excipient excellence.
Goch, July 4, 2018 – DFE Pharma, a global excipient supplier servicing the pharmaceutical industry, has successfully optimized its supply chain of pharmaceutical excipients further. The company has invested heavily in capacity expansion at their factories to meet the global demand for high quality excipients, namely pharmaceutical grade Lactose and Microcrystalline Cellulose (MCC).